SOURCE: Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation

July 15, 2010 09:00 ET

Radient Pharmaceuticals Launches New Investor Video Channel

TUSTIN, CA--(Marketwire - July 15, 2010) -   Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today it has launched a new investor video channel on its corporate website ( to deliver regularly scheduled, dynamic video content to Wall Street and the investing community. The videos are also available at:

Investor communications through RPC's new investor video channel will be delivered on a regular basis and will cover a broad range of topics and information, including personalized messages from RPC's executive team, breaking company news, and in-depth updates on the Company's business and product commercialization strategy, execution, timeline and progress. RPC also plans to leverage its online video channel as a medium to communicate to other key audiences beginning in the third quarter of 2010. Targeted audiences include distributors, strategic partners, oncologists, general practice physicians and cancer patients who may have used or are considering using RPC's Onko-Sure in vitro diagnostic cancer test. 

"Video is becoming increasingly important as a way of reaching investors and business partners with valuable information," commented RPC's Chairman and CEO Mr. Douglas MacLellan. "RPC's new Investor Video Channel is an excellent complement to our just launched corporate website and an excellent channel to communicate business activities that are of material importance our investing community."

Updates on the availability of new content will be broadly communicated through the issuance of press releases. For additional information on RPC visit the Company's website located at or contact RPC Investor Relations at 206.310.5323 or

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is a pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic and therapeutic products, including the company's Onko-Sure in vitro diagnostic (IVD) cancer test -- a simple, non-invasive, patent-pending and regulatory-approved test used for the detection, screening, and monitoring of various types of cancer. Onko-Sure is approved by: the US FDA for the monitoring of colorectal cancer; Health Canada as a lung cancer screen and as a cancer monitoring tool; and as a cancer monitoring or cancer screening test in the European Union, India, Korea, and Taiwan. Visit for additional information.

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Contact Information

  • Radient Pharma Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    Email Contact
    (Tel : ) 206.310.5323